Novavax, Inc. · NASDAQ:NVAX
Novavax — Q3 2026 Earnings Presentation
30 slides from Novavax's earnings presentation, Nov 5, 2026

Slide 1: Third Quarter 2026 Financial Results & Operational Highlights
Third Quarter 2026 Financial Results & Operational Highlights November 5, 2026 © 2026 NOVAVAX. All rights reserved. 1

Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” "target," “g

Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company presents the following non-GAAP financial measures in this presentation: Adjusted Total Revenue, Adjusted Licensing, Royalties and Other Revenue, Non-GAAP combined R&D and SG&A expenses, net of partner reimbursement, non-GAAP R&D expenses, net of partner reimb

Slide 4: Q3 2026 Earnings Call Agenda
Q3 2026 Earnings Call Agenda Welcome 01 Naina Zaman Director, Investor Relations Quarter Overview 02 John C. Jacobs President and Chief Executive Officer Business Development 03 Elaine O’Hara Executive Vice President, Chief Strategy Officer Research and Development 04 Bob Walker, MD Executive Vice P

Slide 5: Three Strategic Pillars Driving Long-Term Value
Three Strategic Pillars Driving Long-Term Value • Partnering our vaccine technology Maximize value from existing collaborations while building the next generation of licensing opportunities • Targeted and capital-efficient R&D innovation Generate data to support partnering discussions, expand utilit

Slide 6: Novavax Today: A Differentiated Vaccine Technology Company
Novavax Today: A Differentiated Vaccine Technology Company Q3 2026 & Recent Highlights • In October, Novavax earned a $125M milestone following Sanofi’s Ph3 CIC trial initiation in the EU and Sanofi intends to initiate a U.S. Phase 3 CIC trial in 20271 to support U.S. approval Partnering our vaccine

Slide 7: Business Development Update
Business Development Update © 2026 NOVAVAX. All rights reserved. 7

Slide 8: Partnership Strategy Focused on Near- and Long-Term Value Creation
Partnership Strategy Focused on Near- and Long-Term Value Creation Maximize value from existing Build the next generation of collaborations licensing opportunities © 2026 NOVAVAX. All rights reserved. 8

Slide 9: Nuvaxovid 2026-2027 Season
Nuvaxovid 2026-2027 Season XFG-adapted Nuvaxovid approved in major United States European Union Japan markets The only non-mRNA option in the U.S. Promoting Nuvaxovid in Japan Commercial Direct-to-consumer New ex-U.S. markets World’s third-largest expertise outreach pharmaceutical market Seasoned va

Slide 10: Partnership Value Creation
Partnership Value Creation Partnerships & Near- to Mid-Term Mid- to Long-Term Collaborations • Achieved $125M milestone for CIC Phase 3 initiation • $225M milestone upon CIC launch in the U.S.1 • Nuvaxovid royalties • Up to $200M in milestones per product plus royalties for each new commercialized a

Slide 11: Research & Development Update
Research & Development Update © 2026 NOVAVAX. All rights reserved. 11

Slide 12: R&D Innovation Fueling Partnerships
R&D Innovation Fueling Partnerships Data fuels new partnerships or expansion of existing partnerships with potential for initial upfront payments, development milestones and royalties Generate data for Expand utility of our Advance select partnering Matrix technology innovative vaccine discussions p

Slide 13: Focused R&D: Where We're Building Evidence
Focused R&D: Where We’re Building Evidence Building evidence for our technology and advancing select vaccine candidates INFECTIOUS DISEASE ONCOLOGY PLATFORM INNOVATION Matrix-M + Licensed Exploratory Preclinical Studies Exploring Further Applications Commercial Vaccines with Novavax Technology • Com

Slide 14: Advancing our Differentiated C. diff Candidate
Advancing our Differentiated C. diff Candidate C. diff: Novavax Vaccine A life-threatening bacterial infection for Why it Matters Candidate4 at-risk populations* with no approved vaccine today Proven adjuvant to potentially drive broader, more potent Matrix-M® adjuvanted 500k cases of C. diff in the

Slide 15: Financial Results
Financial Results © 2026 NOVAVAX. All rights reserved. 15

Slide 16: Q3 2026 Financial Update: Progress on Growth Strategy
Q3 2026 Financial Update Progress on Growth Strategy Partner commercial execution • Quarterly results demonstrate (Sanofi + Takeda + Serum Institute) Q3 2026 Financial Results continued strong execution 41% lower YoY GAAP Combined R&D and SG&A for Q3 2026 • $125M CIC Phase 3 study milestone Sanofi M

Slide 17: Q3 2026 Total Revenue
Q3 2026 Total Revenue $ in Q3 2026 Highlights millions ($2M) YoY Change 75 $70M $68M 13 o +$12 million higher Product sales (+91% YoY) Product Sales 26 o +$11 million deferred royalty revenue 50 Product Sales o ($42) million lower R&D reimbursement o +$16 million all other YoY changes 57 25 43 Licen

Slide 18: Q3 2026 Financial Results
Q3 2026 Financial Results (unaudited) ($ in millions, except per share amounts) Q3 2026 Q3 2025 Product sales $ 26 $ 13 Licensing, royalties, and other 43 57 Total revenue 68 70 Cost of sales 23 21 Research and dev elopment 52 98 Selling, general, and administrativ e 24 32 Key drivers of YoY change

Slide 19: Q3 2026 Combined R&D and SG&A Expense
Q3 2026 Combined R&D and SG&A Expense Significant progress on cost reduction GAAP Q3 YoY trends highlight (41%) continued improvements $ in Non-GAAP millions 130 GAAP Non-GAAP (14%) R&D (47%) (7%) SG&A (25%) (25%) 84 76 72 Total (41%) (14%) R&D R&D Non-GAAP combined R&D and SG&A is net of partner re

Slide 20: Full Year 2026 Revenue Framework & Expense Guidance
Full Year 2026 Revenue Framework & Expense Guidance Full Year 2026 Revenue Framework Full Year 2026 Full Year 2026 $ in millions (as of Nov 5, 2026) (as of Aug 6, 2026) Raising range Nuvaxovid Product Sales1 $40 - $50 $35 - $45 for FY 2026 Framework Adjusted Supply Sales2 $50 - $60 $45 - $55 Sanofi

Slide 21: Full Year 2026 Revenue Framework Footnotes (See Slide 20)
Full Year 2026 Revenue Framework Footnotes (See Slide 20) Revenue Categories Revenue Framework Footnotes Nuvaxovid Product Sales1 $40 million to $50 million in Nuvaxovid Product Sales by Novavax under existing APA and commercial agreements. Expect to exclude from the 2027 Revenue Framework. Adjusted

Slide 22: Non-GAAP Combined R&D and SG&A Expense Guidance
Non-GAAP Combined R&D and SG&A Expense Guidance1,2,3,4 Targeting a >$200M and >50% $ in decrease as partner and APA millions Novavax path to achieve 408 support activities are completed a lean and agile 400 operating model 325 o Complete partner and APA ~$125M Partner 225 support activities and APA

Slide 23: Financial Objectives and Value Creation
Financial Objectives and Value Creation Drive revenue from a diversified set of license partners and products to deliver long-term cash flow growth Targeted and capital-efficient R&D investment to drive long-term value creation • Generate a library of data to enable Matrix-M partnering • Expand util

Slide 24: Closing Remarks
Closing Remarks © 2026 NOVAVAX. All rights reserved. 24

Slide 25: Novavax 2026 & Beyond
Novavax 2026 & Beyond YEAR-TO-DATE HIGHLIGHTS POTENTIAL FUTURE MILESTONES & CATALYSTS ✓ Novavax earned $125M milestone as Sanofi launches • Sanofi's initiation of a U.S. Phase 3 CIC Phase 3 CIC vaccine trial in Europe vaccine trial in 2027 to support U.S. approval • Nuvaxovid manufacturing technolog

Slide 26: Q&A
Q&A © 2026 NOVAVAX. All rights reserved. 26

Slide 27: Appendix
Appendix © 2026 NOVAVAX. All rights reserved. 27

Slide 28: Q3 2026 and Year to Date 2026 Total Revenue
Q3 2026 and Year to Date 2026 Total Revenue Third Quarter Year to Date $ in millions Q3 2026 Q3 2025 Change % FY 2026 FY 2025 Change % Product Sales1 $ 26 $ 13 $ 12 91% $ 87 $ 646 $ (559) (87%) Sanofi 2 19 48 (30) (61%) 103 288 (185) (64%) Pfizer 0 0 0 NM 30 0 30 100% Takeda 7 6 1 14% 8 34 (25) (75%

Slide 29: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results Twelve Months (unaudited) Three Months Ended Nine Months Ended Ended ($ in millions) September 30, September 30, December 31, 2026 2025 2026 2025 2025 R&D Expenses $52.4 $98.3 $218.6 $266.4 $342.3 Adjustments: R&D Reimbursement 3.8 45.8 54.1 63.6

Slide 30: © 2026 NOVAVAX. All rights reserved.
© 2026 NOVAVAX. All rights reserved. 30
Source: 6ix earnings call
More decks from Novavax, Inc.
Q2 2026 Earnings Presentation29 slides · Aug 6, 2026
Q1 2026 Earnings Presentation34 slides · May 6, 2026
Q4 2025 Earnings Presentation35 slides · Feb 26, 2026
J.P. Morgan Healthcare Conference 202615 slides · Jan 12, 2026
Goldman Sachs 46th Annual Global Healthcare Conference (June 2025)24 slides · Jun 11, 2025
Q1 2025 Earnings Presentation18 slides · May 8, 2025